Abstract
Background and Objective: Recombinant human C1 -inhibitor (rhC1INH) is used to treat acute angioedema attacks in hereditary angioedema (HAE) due to a genetic C1INH deficiency. Recombinant proteins in general may induce antibody responses and therefore evaluation of such responses in the target population is an essential step in the clinical development program of a recombinant protein. Here we report the assessment of the immunogenicity of rhC1INH in symptomatic HAE patients.
Methods: Blood samples collected before and after administration of rhC1INH were tested for antibodies against plasma-derived (pd) or rhC1INH, or against host-related impurities (HRI). Above cut-off screening results were confirmed with displacement assays, and also tested for neutralizing anti-C1INH antibodies. Finally, the relation of antibodies to clinical efficacy and safety of rhC1INH was analyzed.
Results: Data from 155 HAE patients who received 424 treatments with rhC1INH were analyzed. 1.5% of all pre-exposure tests and 1.3% of all post-exposure tests were above the cut-off level in the screening assay for anti-C1INH antibodies. Six patients (3.9%) had anti-rhC1INH antibodies positive in the confirmatory assay. In two patients, confirmed antibodies were pre-existing with no increase post-exposure; in three patients, the antibodies occurred on a single occasion post-exposure; and in one patient, on subsequent occasions post-exposure. Neutralizing anti-pdC1INH antibodies were not found. Anti-HRI antibodies in the screening assay occurred in <0.7% of the tests before exposure to rhC1INH, in < 1.9% after first exposure and in <3.1 % after repeat treatment with rhC1INH. Five patients had anti-HRI antibodies positive in the confirmatory assay. In one patient, the antibodies were preexisting, whereas in three of the 155 rhC1INH-treated patients (1.9%), confirmed anti-HRI antibodies occurred at more time points. Antibody findings were not associated with altered efficacy of rhC1INH or adverse events.
Conclusion: These results indicate a reassuring immunosafety profile of rhC1INH as a treatment for acute HAE attacks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med 1963; 35: 37–44
Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med 2008; 359: 1027–36
Rosen FS, Pensky J, Donaldson VH, et al. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148: 957–8
Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114 (Suppl.): S51–131
Cicardi M, Zanichelli A. Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today (Barc) 2010; 46: 867–74
Jahn EM, Schneider CK. How to systematically evaluate immunogenicity of therapeutic proteins: regulatory considerations. N Biotechnol 2009; 25: 280–6
Schellekens H. The immunogenicity of therapeutic proteins. Discov Med 2010; 9: 560–4
Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008; 333: 1–9
European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf [Accessed 2011 Sep 5]
Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47: 1028–32
Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821–7
Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1–16
Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23: 379–96
Varga L, Fust G, Csuka D, et al. Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema. Mol Immunol 2011; 48: 572–6
Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks: final results of the IMPACT2 study. Allergy 2011; 66: 1604–11
Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51–64
Hack CE, Baboeram A, Relan A, et al. IgE against rabbit allergens and the therapeutic use of recombinant human C1 inhibitor (rhC1INH) in hereditary angioedema (HAE), Poster Sessions. Allergy 2010; 65: 209–682
Acknowledgements
All studies were funded by Pharming Technologies BV, Leiden, the Netherlands. The authors would like to thank Prof. M. Cicardi for providing plasma samples from patients with antibodies against C1INH, and QPS Laboratories for performing the antibody measurements. Medical writing support was provided by Rick Flemming, PhD, CMPP, at The Word Bureau and was funded by Pharming Technologies BV.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hack, C.E., Mannesse, M., Baboeram, A. et al. Immunogenicity Assessment of Recombinant Human C1-Inhibitor. BioDrugs 26, 303–313 (2012). https://doi.org/10.1007/BF03261888
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03261888